journal article·2024-01-31Open access

A Biomimetic Multifunctional Nanoframework for Symptom Relief and Restorative Treatment of Acute Liver Failure

Ruibing Feng, Yu Fan, Xinya Zhang, Lanmei Chen, Zhang-Feng Zhong, Yitao Wang, Hua Yu, Qing-Wen Zhang, Guodong Li

Abstract

Acute liver failure (ALF) is a rare and serious condition characterized by major hepatocyte death and liver dysfunction. Owing to the limited therapeutic options, this disease generally has a poor prognosis and a high mortality rate. When ALF cannot be reversed by medications, liver transplantation is often needed. However, transplant rejection and the shortage of donor organs still remain major challenges. Most recently, stem cell therapy has emerged as a promising alternative for the treatment of liver diseases. However, the limited cell delivery routes and poor stability of live cell products have greatly hindered the feasibility and therapeutic efficacy of stem cell therapy. Inspired by the functions of mesenchymal stem cells (MSCs) primarily through the secretion of several factors, we developed an MSC-inspired biomimetic multifunctional nanoframework (MBN) that encapsulates the growth-promoting factors secreted by MSCs via combination with hydrophilic or hydrophobic drugs. The red blood cell (RBC) membrane was coated with the MBN to enhance its immunological tolerance and prolong its circulation time in blood. Importantly, the MBN can respond to the oxidative microenvironment, where it accumulates and degrades to release the payload. In this work, two biomimetic nanoparticles, namely, rhein-encapsulated MBN (RMBN) and N-acetylcysteine (NAC)-encapsulated MBN (NMBN), were designed and synthesized. In lipopolysaccharide (LPS)/d-galactosamine (D-GalN)-induced and acetaminophen (APAP)-induced ALF mouse models, RMBN and NMBN could effectively target liver lesions, relieve the acute symptoms of ALF, and promote liver cell regeneration by virtue of their strong antioxidative, anti-inflammatory, and regenerative activities. This study demonstrated the feasibility of the use of an MSC-inspired biomimetic nanoframework for treating ALF.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Liver physiology and pathology · Organ Transplantation Techniques and Outcomes · Nanoplatforms for cancer theranostics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, P. R. China

Macao Centre for Research and Development in Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao SAR 999078, P. R. China

Zhuhai UM Science and Technology Research Institute, Zhuhai 519031, P.R. China

The Marine Biomedical Research Institute of Guangdong Zhanjiang, School of Ocean and Tropical Medicine, Guangdong Medical University, Zhanjiang, Guangdong 524023, P.R. China

Funding

Universidade de Macau · Basic and Applied Basic Research Foundation of Guangdong Province · Fundo para o Desenvolvimento das Ciências e da Tecnologia · National Natural Science Foundation of China

References (57)

Show source-provided references
1. 10.1038/s41591-020-1102-210.1038/s41591-020-1102-2 ↗
2. Lee W. M. · 2022 · 188910.1002/9781119600206.ch90 ↗
3. 10.1002/ncp.1046210.1002/ncp.10462 ↗
4. 10.1002/lt.2544510.1002/lt.25445 ↗
5. 10.15212/AMM-2022-003910.15212/AMM-2022-0039 ↗
6. 10.1038/s41392-017-0004-310.1038/s41392-017-0004-3 ↗
7. 10.1038/s41578-019-0108-110.1038/s41578-019-0108-1 ↗
8. 10.1002/adma.20221162610.1002/adma.202211626 ↗
9. 10.1002/smll.20220621110.1002/smll.202206211 ↗
10. 10.7150/thno.3793010.7150/thno.37930 ↗
11. 10.1002/adfm.20160579510.1002/adfm.201605795 ↗
12. 10.1016/j.mtbio.2022.10022810.1016/j.mtbio.2022.100228 ↗
13. 10.1021/acsnano.8b0055310.1021/acsnano.8b00553 ↗
14. 10.1002/adhm.20230057110.1002/adhm.202300571 ↗
15. 10.1002/adma.20210834810.1002/adma.202108348 ↗
16. 10.1038/s41563-019-0378-410.1038/s41563-019-0378-4 ↗
17. 10.1016/j.jhep.2016.11.01710.1016/j.jhep.2016.11.017 ↗
18. 10.1016/j.ijbiomac.2022.08.02910.1016/j.ijbiomac.2022.08.029 ↗
19. 10.1038/s41467-022-31881-510.1038/s41467-022-31881-5 ↗
20. 10.1186/s13287-022-02825-z10.1186/s13287-022-02825-z ↗
21. 10.1038/s41392-021-00754-610.1038/s41392-021-00754-6 ↗
22. 10.1038/s42003-022-03833-810.1038/s42003-022-03833-8 ↗
23. 10.1177/096368971983789710.1177/0963689719837897 ↗
24. 10.1038/s41392-022-00932-010.1038/s41392-022-00932-0 ↗
25. 10.2147/IJN.S8838410.2147/IJN.S88384 ↗
26. 10.1021/acsomega.2c0107110.1021/acsomega.2c01071 ↗
27. 10.2147/IJN.S8838410.2147/IJN.S88384 ↗
28. 10.3390/pharmaceutics1309145210.3390/pharmaceutics13091452 ↗
29. 10.3390/polym1404068710.3390/polym14040687 ↗
30. 10.1155/2015/57810710.1155/2015/578107 ↗
31. 10.1016/S0009-2797(96)03747-710.1016/S0009-2797(96)03747-7 ↗
32. 10.1080/01480545.2020.180967010.1080/01480545.2020.1809670 ↗
33. 10.1155/2015/32983110.1155/2015/329831 ↗
34. 10.12659/MSM.92572710.12659/MSM.925727 ↗
35. 10.1093/jpp/rgac06210.1093/jpp/rgac062 ↗
36. 10.3389/fimmu.2022.97140910.3389/fimmu.2022.971409 ↗
37. 10.1186/s13020-023-00764-210.1186/s13020-023-00764-2 ↗
38. 10.1016/j.ejphar.2021.17390810.1016/j.ejphar.2021.173908 ↗
39. 10.1073/pnas.110663410810.1073/pnas.1106634108 ↗
40. 10.1007/s12265-010-9171-010.1007/s12265-010-9171-0 ↗
41. 10.1016/j.apsb.2019.01.01610.1016/j.apsb.2019.01.016 ↗
42. 10.1039/C9SC05623H10.1039/C9SC05623H ↗
43. 10.1038/cdd.2013.13810.1038/cdd.2013.138 ↗
44. 10.1186/s13020-022-00573-z10.1186/s13020-022-00573-z ↗
45. 10.1016/j.phrs.2016.06.02210.1016/j.phrs.2016.06.022 ↗
46. 10.1016/j.inoche.2016.04.02510.1016/j.inoche.2016.04.025 ↗
47. 10.3390/ph1601001410.3390/ph16010014 ↗
48. 10.1016/j.ijbiomac.2018.07.10110.1016/j.ijbiomac.2018.07.101 ↗
49. 10.1016/j.ejps.2023.10641310.1016/j.ejps.2023.106413 ↗
50. Petrò L. · 2022 · 1910.1007/978-3-031-14612-1_2 ↗
51. 10.1007/s40820-020-00550-x10.1007/s40820-020-00550-x ↗
52. 10.1111/hepr.1354910.1111/hepr.13549 ↗
53. 10.1016/j.redox.2021.10212910.1016/j.redox.2021.102129 ↗
54. 10.1186/s12967-022-03495-410.1186/s12967-022-03495-4 ↗
55. 10.1155/2021/458241210.1155/2021/4582412 ↗
56. 10.3389/fphar.2022.82856510.3389/fphar.2022.828565 ↗
57. 10.1016/j.nano.2017.08.01710.1016/j.nano.2017.08.017 ↗